Skip to content

Castle Biosciences

US · CSTL #3242 by market cap Listed 2019
32.86 -0.55 -1.63%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 32.68 -2.17%
After-hours 32.86 0.00%
38.5119.6932.862026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on CSTL?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -4.1% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 6.9% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability C

How much profit the business keeps from each dollar of sales and capital.

Gross margin 79.4% Better than 90%
Operating margin -12.4% Better than 14%
Net margin -7.0% Better than 17%
Return on equity -5.2% Better than 23%
Return on invested capital -6.8% Better than 20%
Momentum B

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -3.9% Better than 65%
6-month return 63.1% Better than 97%
12-month return (ex latest month) -12.7% Better than 20%
Distance below 52-week high 25.8% Better than 49%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 5.3x Better than 87%
Debt to assets 6.4% Better than 76%
Interest coverage -342.2x Better than 3%
Free cash flow / net income 200.3% Better than 77%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 47.0% Better than 64%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -2.75%
1M -0.87%
3M -0.21%
6M +64.05%
YTD -15.53%
1Y -8.01%
3Y +63.81%
5Y -30.82%

Key statistics

Price & volume

Prev close
33.41
Open
32.76
Day range
32.54 - 33.38
Avg price
32.85
Volume
309.22K
Turnover
10.16M
Amplitude
2.53%
52-week range
17.72 - 44.28

Valuation

P/E
-39.59
P/E (TTM)
-43.24
P/B
2.12
EPS
-0.83
Net profit
-25.58M
Net assets
478.45M

Share structure

Market cap
1.01B
Float cap
902.87M
Shares out
30.82M
Float shares
27.48M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2019-07-25
52-week range 57% of range
17.72 44.28

25.8% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-3.55M net over the window

Short interest

Shares short
2.11M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Castle Biosciences (CSTL)?

Castle Biosciences last traded at 32.86. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Castle Biosciences's market cap?

About 1.01B.

What is the P/E ratio of Castle Biosciences?

The trailing twelve-month P/E is -43.24. The Valuation tab shows it against the stock's own five-year range.

Does Castle Biosciences pay a dividend?

Castle Biosciences does not currently pay a regular dividend.

Is Castle Biosciences a buy according to analysts?

The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 48.29, which implies 47.0% upside from the current price. This is not investment advice.

What is Castle Biosciences's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Castle Biosciences a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Castle Biosciences discussion 0 comments

Add a comment